Emergency Curative Resection of Colorectal Cancer, Do it With Caution. A Comparative Case Series
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 215
- 主要终点
- early postoperative morbidity after curative resection of colorectal cancer
研究概览
简要总结
The feasibility and efficacy of emergency curative resection of complicated colorectal cancer is still controversial. This prospective study aim is to assess surgical and oncologic outcomes after emergency compared to elective curative resection of colorectal cancer
详细描述
60 consecutive patients presented with complicated colorectal cancer managed by emergency surgery were included and compared to another 155 consecutive patients admitted during the same period with uncomplicated colorectal cancer managed by elective surgery. Both groups were compared regarding curative resection rate, early postoperative mortality and morbidity, 3-years tumor recurrence and survival rates.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients presented with Potentially operable colorectal cancer
- •No clinical or radiological evidence of metastatic disease
排除标准
- •Patients received preoperative chemoradiation
- •Patients with clinical or radiological evidence of metastatic disease
- •Patients with intraoperative evidence of metastatic disease
- •Patients with intraoperative evidence of irresectable disease
- •Patients with incomplete follow up
结局指标
主要结局
early postoperative morbidity after curative resection of colorectal cancer
时间窗: within 90 days after surgery
surgery-related complications
early postoperative mortality after curative resection of colorectal cancer
时间窗: within 90 days after surgery
early death due to cause related to surgery
Adequate oncologic resection
时间窗: histopathological assessment of surgical specimens within 2 weeks postoperative
Negative resection margins + adequate lymphadenectomy ( Lymph Nodes retrieved \> 12)
次要结局
- Disease free survival(By the end of the 3 years follow up period)
- Overall survival(By the end of the 3 years follow up period)
- Tumor recurrence(By the end of the 3 years follow up period)
研究者
Mohamed El Messiry
Ass. Professor
University of Alexandria